PMID- 24527093
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211021
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 7
IP  - 3
DP  - 2014 Mar
TI  - Role of mTOR inhibitor in cholangiocarcinoma cell progression.
PG  - 854-860
AB  - Cholangiocarcinoma (CCA) is a lethal malignancy of the biliary epithelium. CCA is 
      resistant to currently available chemotherapy; therefore, new drugs as well as 
      new molecular targets must be identified for the development of an effective 
      treatment for CCA. The present study showed that RAD001 (everolimus), a 
      derivative of rapamycin and an orally bioavailable mammalian target of rapamycin 
      (mTOR) inhibitor, exhibits cytotoxic and antimetastatic effects in a CCA cell 
      line, RMCCA-1. Treatment with low concentrations of RAD001 resulted in a 
      significant reduction of in vitro invasion and migration of RMCCA-1, concomitant 
      with a reduction of filopodia and alteration of the actin cytoskeleton. Although, 
      matrix metalloproteinase-9 and -14 activities were unaltered. However, at high 
      concentrations, RAD001 exhibited cytotoxic effects, reducing cell proliferation 
      and inducing apoptotic cell death. Overall, RAD001 exhibits multiple effects 
      mediated by the inhibition of the mTOR, which may serve as a promising agent for 
      the treatment of CCA.
FAU - Moolthiya, Penpak
AU  - Moolthiya P
AD  - Department of Biochemistry, Faculty of Science, Mahidol University, Rajathevi, 
      Bangkok 10400, Thailand.
FAU - Tohtong, Rutaiwan
AU  - Tohtong R
AD  - Department of Biochemistry, Faculty of Science, Mahidol University, Rajathevi, 
      Bangkok 10400, Thailand.
FAU - Keeratichamroen, Siriporn
AU  - Keeratichamroen S
AD  - Department of Molecular Medicine, Faculty of Science, Mahidol University, 
      Rajathevi, Bangkok 10400, Thailand.
FAU - Leelawat, Kawin
AU  - Leelawat K
AD  - Department of Surgery, Rajavithi Hospital, Rajathevi, Bangkok 10400, Thailand.
LA  - eng
PT  - Journal Article
DEP - 20140115
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC3919862
OTO - NOTNLM
OT  - RAD001
OT  - cholangiocarcinoma
OT  - mTOR inhibitor
EDAT- 2014/02/15 06:00
MHDA- 2014/02/15 06:01
PMCR- 2014/01/15
CRDT- 2014/02/15 06:00
PHST- 2013/05/31 00:00 [received]
PHST- 2013/11/29 00:00 [accepted]
PHST- 2014/02/15 06:00 [entrez]
PHST- 2014/02/15 06:00 [pubmed]
PHST- 2014/02/15 06:01 [medline]
PHST- 2014/01/15 00:00 [pmc-release]
AID - ol-07-03-0854 [pii]
AID - 10.3892/ol.2014.1799 [doi]
PST - ppublish
SO  - Oncol Lett. 2014 Mar;7(3):854-860. doi: 10.3892/ol.2014.1799. Epub 2014 Jan 15.